Key Points {#FPar1}
==========

A comprehensive assessment of the research literature on pharmacotherapy for amphetamine/methamphetamine dependence may inform treatment guidelines and future research directions.We systematically reviewed 43 randomised controlled trials enrolling 4065 participants and assessing 23 pharmacotherapies for amphetamine/methamphetamine dependence.Outcomes and measures to assess them varied widely, making it difficult to synthesise the data; pharmacotherapies were most often assessed in defined or biased populations, and study completion rates were low.No pharmacotherapy demonstrated convincing results; however, some agents demonstrated promise, suggesting further, larger studies are required.Future research should consider the heterogeneity of amphetamine/methamphetamine dependence and the role of psychosocial intervention.

Introduction {#Sec1}
============

Amphetamines and other stimulant drugs are second only to cannabis as the most widely used class of (illicit) drugs globally, accounting for 68 million past-year consumers \[[@CR1]\]. Approximately 29 million people worldwide aged 15--65 years were estimated to have consumed amphetamines in the past year to 2017 \[[@CR1]\].

Amphetamines refer to both amphetamine (AMPH) and the structurally similar methamphetamines (MA), both of which are used extra-medically. MA is considered a more potent derivative of AMPH, with a longer duration of action and increased ability to cross the blood--brain barrier; and global shifts in the illicit stimulant market have resulted in the predominance of MA \[[@CR2], [@CR3]\].

Amphetamines act on the central nervous system (CNS) and acute effects include a heightened sense of alertness; increased energy; heightened curiosity; anorexia; decreased fatigue; elevated mood; dose-dependent effects on focus, attention and concentration; and elevated interest in environmental stimuli \[[@CR3], [@CR4]\]. Extra-medical use of AMPH and MA is usually at higher doses than those prescribed orally, and through routes of administration that result in more rapid onset (inhaled, injected intravenously, intra-nasal, per-vaginal, and per-rectal). Extra-medical consumption of amphetamines may be for enjoyment and/or for performance enhancement (such as for night-shift workers to enable longer working hours) \[[@CR5]\].

The effects of chronic and regular high-dose AMPH/MA use are more complex than occasional use, and may involve the development of a substance use disorder---characterised by social and physiological (e.g. tolerance, withdrawal) manifestations \[[@CR5]\]. The Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) criteria for Stimulant Use Disorder (SUD) and Stimulant Withdrawal \[[@CR6]\] are listed in Table [1](#Tab1){ref-type="table"}. In the previous version of the DSM (DSM-IV) \[[@CR7]\], the classification listed 'dependence' rather than 'use disorder'; with 'moderate to severe' SUD being regarded as equivalent to 'dependence'. The International Classification of Diseases (ICD) 10th Revision (ICD-10) recognises 'stimulant dependence syndrome' and 'stimulant withdrawal state' \[[@CR8]\]. However, neither diagnostic tool differentiates between AMPH/MA and other non-cocaine stimulant SUDs; while the 11th Revision of the ICD narrows the definition to "stimulant dependence including amphetamines, methamphetamine or methcathinone" \[[@CR9]\]. In this paper, we have reviewed articles using all of the above classifications and sometimes interchangeably and our search included both terms. Most reviewed articles had eligibility criteria that included either the DSM-IV or DSM-V diagnostic criteria, and so we have combined the terms as dependence/use disorder.Table 1DSM-V diagnostic criteria for stimulant use disorderDSM-V: stimulant use disorder \[[@CR6]\]DSM-V: stimulant withdrawal \[[@CR6]\]AA pattern of amphetamine-type substance (ATS), cocaine, or other stimulant use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period: 1. The stimulant is often taken in larger amounts or over a longer period than was intended 2. There is a persistent desire or unsuccessful efforts to cut down or control stimulant use 3. A great deal of time is spent in activities necessary to obtain the stimulant, use the stimulant, or recover from its effects 4. Craving, or a strong desire or urge to use the stimulant 5. Recurrent stimulant use resulting in a failure to fulfil major role obligations at work, school, or home 6. Continued stimulant use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the stimulant 7. Important social, occupational, or recreational activities are given up or reduced because of stimulant use 8. Recurrent stimulant use in situations where it is physically hazardous 9. Stimulant use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the stimulant 10. Tolerance, as defined by either of the following:  a. A need for markedly increased amounts of the stimulant to achieve intoxication or desired effect  b. A markedly diminished effect with continued use of the same amount of the stimulantNote: this criterion is not considered to be met for those taking stimulant medications solely under appropriate medical supervision, such as medications for attention-deficit/hyperactivity disorder or narcolepsy 11. Withdrawal, as manifested by either of the following:  a. The characteristic withdrawal syndrome for the stimulant (refer to criteria A and B of the criteria set for Stimulant Withdrawal)  b. The stimulant (or a closely related substance) is taken to relieve or avoid withdrawal symptomsNote: this criterion is not considered to be met for those taking stimulant medications solely under appropriate medical supervision, such as medications for attention-deficit/hyperactivity disorder or narcolepsySpecify if:In early remission: After full criteria for SUD were previously met, none of the criteria for SUD have been met for at least 3 months but for less than 12 months (with the exception that criterion A4, "Craving, or a strong desire to use the stimulant," may be met)In sustained remission: After full criteria for SUD were previously met, none of the criteria for SUD have been met at any time during a period of 12 months or longer (with the exception of criterion A4, "Craving, or a strong desire to use the stimulant," may be met)Specify if:In a controlled environment: This additional specifier is used if the individual is in an environment where access to stimulants is restrictedACessation of (or reduction in) prolonged amphetamine-type substance, cocaine, or other stimulant useBDysphoric mood and two (or more) of the following physiological changes, developing within a few hours to several days after Criterion A: 1. Fatigue 2. Vivid, unpleasant dreams 3. Insomnia or hypersomnia 4. Increased appetite5. Psychomotor retardation or agitationCThe signs and symptoms of Criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioningDThe signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication or withdrawal from another substance*DSM*-*V* Diagnostic and Statistical Manual of Mental Disorders fifth edition, *SUD* stimulant use disorder

Globally, it is estimated that 7.4 million people are dependent on amphetamines, and that dependence affects 11% of people who use amphetamines \[[@CR10]\]. Regular or dependent AMPH/MA use is associated with comorbidities including depression, anxiety, psychosis and cardiovascular disease, and is due to contextual social factors related to the consumption of AMPH/MA, sexually transmitted infections or blood borne viruses and legal issues \[[@CR11], [@CR12]\]. Globally, the United Nations Office of Drugs and Crime (UNODC) estimates around one in seven people with substance use disorders receives treatment \[[@CR1]\], and that the proportion of people with stimulant use disorder in treatment is under-represented compared with opioid use disorder, for which there are effective treatments combining medication and psychosocial interventions \[[@CR13]\].

Psychosocial therapies have been trialled for AMPH/MA dependence with varying efficacy \[[@CR14], [@CR15]\]. These include Cognitive Behavioural Therapy (CBT), Contingency Management (CM), Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT). Even short periods of intervention with CBT (1--2 sessions) demonstrate a reduction in MA use in people who are dependent on MA \[[@CR14]\]. CM has demonstrated significant reduction in stimulant use \[[@CR16]\] alone, or in combination with CBT \[[@CR16]\] or a community reinforcement approach \[[@CR17]\]. However, the effects of psychosocial therapies are often not sustained following their cessation \[[@CR14], [@CR18]\], and are less effective for severe disorder (long duration, frequent use) \[[@CR19]\]. There have been few controlled evaluations of residential rehabilitation approaches for people with AMPH/MA use disorders. One longitudinal, non-randomised, quasi-controlled study demonstrated that residential rehabilitation was associated with decreased MA use 3 months after treatment compared with detoxification or no treatment, but this effect was not maintained to year 3 of follow-up \[[@CR20]\].

One priority for clinicians and researchers alike has been to establish an effective pharmacotherapy for SUD. Target pharmacotherapies have considered the mechanism of action of AMPH/MA, which affects neurotransmitters through a number of mechanisms. Consumption of MA triggers a cascading release of norepinephrine, dopamine and serotonin. The drug (to a lesser extent) acts as a dopaminergic and adrenergic reuptake inhibitor, and in higher concentrations as a monoamine oxidase inhibitor (MAOI) \[[@CR1], [@CR21]\]. The CNS effects produced by MA are mostly the result of influencing levels of dopamine and norepinephrine, and to a lesser extent serotonin \[[@CR1], [@CR21]\].

Due to the nature of drug dependence research, studies often enrol people using multiple types of stimulants or other drugs. Here we review studies reporting on pharmacotherapies for the treatment of SUD or drug dependence due to AMPH/MA. Specifically, we reviewed randomised studies of participants with MA or AMPH use disorder or dependence (recognising the shift of eligibility criteria and definitions between the DSM-IV and DSM-V) randomised to a pharmacological intervention and compared with a control group, with outcomes related to AMPH/MA use and associated symptoms (e.g. cravings or withdrawal, as these are both listed as features of dependence/use disorder). The aim of the present review is to provide clinicians with a summary of the current status of research on pharmacological treatment of AMPH/MA dependence.

Methods {#Sec2}
=======

We approached this report as a systematic review of the peer-reviewed literature, and present the methods and results in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR22]\].

The eligibility criteria for this review were randomised controlled trials (RCTs) enrolling participants (any age or sex) that assessed a pharmacological treatment (alone or in combination with psychosocial treatment) for the treatment of AMPH/MA dependence or use disorder. The search was limited to human trials and with text in the English language. Included were studies reporting on an outcome related to treatment efficacy as defined by AMPH/MA use, associated symptoms (e.g. cravings or withdrawal) or retention in treatment/care. We excluded human studies that were conducted in a laboratory environment, studies enrolling primarily non-AMPH/MA-dependent participants, animal studies, qualitative studies, general reviews and secondary analyses of RCTs.

A search of the electronic databases PubMed, EMBASE, CINAHL and SCOPUS was conducted. The basic search strategy for all databases was as follows: (amphetamine OR methamphetamine) AND (dependence OR disorder) AND (pharmacological treatment OR pharmacotherapy OR drug therapy). Additional studies were obtained by checking the references of selected articles. There was no start date limitation on the search---the last search date for inclusion was 19 June 2019. An example search strategy is included in Supplementary Fig. 1 (see electronic supplementary material \[ESM\]).

The titles and abstracts of the studies identified by the search strategy were evaluated by two reviewers (KS and LA) independently. Selected publications were read in full by the same two investigators. Divergent selection of publications was discussed among the investigators until a consensus was obtained, and if required a third reviewer (NE) resolved disputes. Data were managed in Covidence \[[@CR23]\] up to the point of data extraction; due to the large variation in outcome measures, data extraction was completed on identical spreadsheets by the two reviewers and compared for consistency. The selected studies were evaluated for design, methodology, inclusion and exclusion criteria, sample size, pharmacological and (if included) psychosocial interventions, length of follow-up and follow-up schedules, outcome variables and measures, results and overall conclusions.

Risk of bias was assessed based on the following features: allocation of participants, blinding of participants or personnel, study sample, study completion rates, analyses of outcomes (e.g. conservative or not with respect to missing data, analysis as intention-to-treat), overstated conclusions and study funding.

This review provides a qualitative, narrative report of the data. Conducting a traditional systematic review and meta-analyses is predicated on the assumption of studies reporting on similar outcomes, using similar outcome measures, and with similar methodology. However, the data we reviewed herein was disparate in respect to the reported outcomes and measures. This prohibited meta-analysis of the literature but allowed for a comprehensive report on the current status of the research.

Results {#Sec3}
=======

Study Selection and Characteristics {#Sec4}
-----------------------------------

Our search returned 43 RCTs that met our criteria \[[@CR24]--[@CR66]\]. A PRISMA flow diagram is presented in Fig. [1](#Fig1){ref-type="fig"}. Forty (93.0%) of these studies were double-blinded \[[@CR24]--[@CR45], [@CR47]--[@CR55], [@CR57]--[@CR65]\]. In total, 39 (90.7%) were placebo controlled, while the remaining four studies (9.3%) were designed with a treatment-as-usual or alternate treatment arm as the control \[[@CR36], [@CR49], [@CR61], [@CR66]\]. The study settings are described in Table [2](#Tab2){ref-type="table"}. The studies were published between 1995 and 2019.Fig. 1PRISMA flow diagramTable 2Study setting and contextSettingNumber of studies (%)Setting Outpatient32 (74.4) Inpatient5 (11.6) Outpatient and inpatient4 (9.3) Not reported2 (4.7)Location United States of America (USA)23 (53.5) Iran7 (16.3) Australia4 (9.3) Malaysia2 (4.7) Thailand2 (4.7) Finland1 (2.3) Finland and New Zealand1 (2.3) Iceland1 (2.3) Russia1 (2.3) Sweden1 (2.3)Enrolling centres Single site26 (60.5) Multi-site16 (37.2) Not reported/unclear1 (2.3)

The 43 studies collectively randomised 4065 participants. Of the 43 studies, 38 (88%) reported on the total number of participants who completed the study, while five studies (12%) did not \[[@CR36], [@CR39], [@CR57], [@CR62], [@CR64]\]. Of the 38 reporting on study completion rates, the total number of participants randomised was 3733 (92% of the total) and of these, 2298 participants completed the study (61.6%).

Of the 4065 participants reported on in the reviewed studies, 2858 (70.3%) were male. Nine of the 43 studies (21%) enrolled only males \[[@CR24], [@CR29], [@CR30], [@CR34], [@CR46], [@CR52], [@CR55], [@CR57], [@CR58]\], however not all of these were by design. One study \[[@CR45]\] did not report the sample by those randomised, only by completers (in a non-intention-to-treat analysis) and so the total randomised figure of men versus women was not able to be determined based on randomisation (authors did not respond to a request for further data).

Thirty of the 43 studies (69.8%) included participants dependent on MA only \[[@CR24]--[@CR30], [@CR32]--[@CR35], [@CR38]--[@CR41], [@CR44], [@CR45], [@CR47]--[@CR50], [@CR53]--[@CR55], [@CR57], [@CR59]--[@CR62], [@CR65]\]; four (9.3%) were on MA/AMPH \[[@CR31], [@CR37], [@CR51], [@CR64]\]; four (9.3%) were on AMPH only \[[@CR42], [@CR43], [@CR46], [@CR56]\]; three (7.0%) were on amphetamine-type stimulants (ATS) and opioids \[[@CR52], [@CR58], [@CR63]\] and two (4.7%) were on MA/cocaine \[[@CR36], [@CR66]\].

The 43 studies examined 23 individual pharmacotherapies, most individually and some in combination. Table [3](#Tab3){ref-type="table"} lists the pharmacotherapies reviewed, and the proposed mechanisms of action related to their use in studies of MA/AMPH dependence.Table 3Pharmacotherapies reviewedPharmacotherapyMechanism of action proposed to be related to use in methamphetamine (MA)/amphetamine (AMPH) dependence*n*Antidepressants AmineptineDopamine reuptake inhibition similar to amphetamines, limited noradrenergic effect \[[@CR85], [@CR86]\]1 MirtazapineNoradrenergic and specific serotonergic antidepressant. Mixed monoamine agonist/antagonist---facilitates release of norepinephrine, serotonin and dopamine in the CNS \[[@CR87]\]3 BupropionAtypical, non-tricyclic antidepressant. Selective inhibitor of the neuronal reuptake of norepinephrine and dopamine, with minimal effect on the reuptake of serotonin and no inhibitory effect on monoamine oxidase; nicotinic acetylcholine receptor agonist \[[@CR88]\]6 SertralineSelective serotonin reuptake inhibitor (SSRI). Blocks the uptake of serotonin \[[@CR89]\]1 AtomoxetineSelective norepinephrine transporter (NET) inhibitor. Potent inhibitor of presynaptic NET, moderate inhibitor of serotonin reuptake and weak inhibitor of dopamine uptake, minimal affinity for other noradrenergic receptors, moderate affinity for 5HT~2~ and GABA~A~ receptors but poor affinity for most other receptors \[[@CR90]\]1Tricyclic antidepressants (TCAs) ImipramineTCAs downregulate catecholamine and serotonin receptors, a proliferation of which is induced by chronic cocaine use \[[@CR91]\]1Atypical antipsychotics AripiprazolePartial agonist activity at dopamine D~2~ and serotonin 5HT~1A~ receptors and antagonist activity at serotonin 5HT~2A~ receptors \[[@CR92]\]2 Aripiprazole + methylphenidate(See above and below)1Anticonvulsants TopiramateEnhances activity of gamma-aminobutyric acid (GABA) at some types of GABA~A~ receptors, glutamate antagonist \[[@CR93]\]2Central nervous system stimulants Dextroamphetamine/dexamphetamineAnalogue of MA, facilitates the action of dopamine and norepinephrine by blocking reuptake from synapse, inhibits action of monoamine oxidase (MAO) \[[@CR94]\]2 MethylphenidateCNS stimulant, presumed mechanism of action is inhibition of dopamine reuptake without triggering the release of dopamine \[[@CR95]\]3Other central nervous system agents ModafinilExact mechanism of action unknown, thought to bind to dopamine reuptake site with low affinity, increasing extracellular dopamine \[[@CR96]\]4GABA~B~ agonist/GABAergic agents Baclofen + gabapentin*Baclofen:* Derivative of GABA, inhibits the release of excitatory amino acids (glutamate and aspartate) \[[@CR97]\]*Gabapentin:* structurally related to GABA neurotransmitter, identification and function of gabapentin binding sites remains to be elucidated \[[@CR98]\]GABAergic agents may act on dopamine transmission and reduce the positive reinforcement of MA \[[@CR99]\]1Opioid agonists Buprenorphineμ-opioid receptor partial agonist, κ-opioid receptor antagonist \[[@CR100]\]1 Buprenorphine + methadone*Methadone:* opioid agonism and N-methyl-d-aspartate (NMDA) antagonism \[[@CR101]\]1Opioid antagonists NaltrexoneOpioid receptor antagonist \[[@CR102]\]. Animal evidence for involvement of endogenous opioid system in MA-seeking behaviours \[[@CR103]\]55HT~3~-receptor antagonist Ondansetron5HT~3~-receptor antagonist, potential to attenuate hyper-dopaminergic behaviours \[[@CR104]\]1Partial cholinergic nicotinic agonist VareniclinePartial agonist at α4β2 neuronal nicotinic acetylcholine receptors; restoration of MA-related dopaminergic and glutamatergic deficits, cholinergic mechanisms \[[@CR105]\]1Glutamatergic agents *N*-acetyl cysteineAmino acid. Reduces the release of glutamate from the synapse by stimulation of inhibitory glutamate receptors \[[@CR106]\]1 *N*-acetyl cysteine + naltrexone(See above)1 RiluzoleGlutamate regulatory effects in the CNS \[[@CR107]\]1CRF1 antagonist PexacerfontCorticotropin-releasing factor (CRF) binds CRF type 1 receptors during MA withdrawal and a CRF1 antagonist would alleviate the anxiety associated with withdrawal due to CRF \[[@CR108], [@CR109]\]1Benzodiazepine antagonist/GABA agonist/H1 histamine receptor Flumazenil + gabapentin + hydroxyzineA combination pharmacotherapy regimen with properties including normalising altered dopamine, glutamate and GABA neurotransmitter function \[[@CR110]\]2*Total studies reviewed/total pharmacotherapy agents reviewed43/23n* Number of reviewed studies investigating this pharmacotherapy

A summary of the reviewed studies is presented in Table [4](#Tab4){ref-type="table"}, and an extended version is available in Supplementary Table 1 (see ESM). In addition, the data collected by both reviewers can be located in its entirety in the Supplementary Data (see ESM).Table 4Reviewed studiesPharmacotherapyDose, duration of treatment and publicationParticipantsKey design elementsResultsAntidepressants Amineptine300 mg OD over 14 days (Jittiwutikan et al., 1997) \[[@CR43]\]*n* = 30, AMPH-dependent, inpatients, drug dependence treatment centre, ThailandDB, PB, analysed as ITT, no psychotherapy, inpatient, Thailand; 300 mg split over 2 uneven dosesMay improve depressed mood over first 7 days of treatment (QECCR). May improve global state after 14 days Mirtazapine30 mg OD over 12 weeks (Colfax et al., 2011) \[[@CR30]\]*n* = 60, MA-dependent MSM, outpatient, USADB, PB, analysed as ITT, CBT and MI, outpatient, USAReduced MA use (UDS), reduced sexual risk behaviours, no change to depressive symptoms (CES-D)30 mg OD over 14 days (Cruickshank et al., 2008) \[[@CR31]\]*n* = 31, ATS dependent, recent use, outpatient, AUSDB, PB, analysed as ITT, narrative therapy, outpatient, AUSDoes not improve retention in treatment. Does not improve withdrawal, depression, anxiety, dependence, use (ACSA, ASI-5, BSI, DASS, SDS, OTI)15--30 mg OD over 14 days (Kongsakon et al., 2005) \[[@CR46]\]*n* = 20, AMPH-dependent, correctional facility, ThailandNB, PB, analysis unclear, no psychotherapy, correctional facility, ThailandReduced withdrawal severity (AWQ). May improve anxiety, no change in depression (MADRS) Bupropion150 mg (SR) BID over 12 weeks (Anderson et al., 2015) \[[@CR26]\]*n* = 204, MA-dependent, use \< 30 days past monthDB, PB, analysed as ITT, CBT, outpatient, USANo difference in abstinence (UDS). Contradicts Elkashef 2008150 mg (SR) BID over 12 weeks (Elkashef et al., 2008) \[[@CR33]\]*n* = 156, MA-dependent, treatment seekingDB, PB, analysis not clear, CBT, outpatient, USANo difference in abstinence (UDS), in low-use participants (\< 18 days per 30) increased abstinence150 mg (SR) BID over 8 weeks (Heinzerling et al., 2013) \[[@CR39]\]*n* = 19, MA-dependent, 14--21 years oldNB, PB, analysed as ITT, group counselling, outpatient, USAStudies are not feasible in this population (MA-dependent adolescents)150 mg (SR) BID over 12 weeks (Heinzerling et al., 2014) \[[@CR41]\]*n* = 84, MA-dependent, treatment seeking, used \< 29 days of past 30DB, PB, analysed as ITT, CBT, outpatient, USANo difference in EOTA (UDS), treatment associated with a higher mean number of participants with negative UDS, but very low medication adherence150 mg (SR) BID over 12 weeks (Shoptaw et al., 2008) \[[@CR60]\]*n* = 73, MA-dependentDB, PB, analysed as ITT, CBT and CM, outpatient, USANo differences in retention, TES (UDS), or craving, depression, smoking (VAS, BDI, cigarette count) Bupropion and nicotine inhaler300 mg (XR) OD over 10 weeks (Winhusen et al., 2014) \[[@CR66]\]*n* = 583 MA-dependent, already engaged as outpatients, smokersNB, treatment-as-usual, analysed as ITT, both arms receive SUD counselling, treatment arm received smoking cessation and CM, outpatients, USANo difference in abstinence (UDS and self-report), smoking reduced in treatment arm (CO level, cigarette count), no difference in substance use (UDS) Sertraline50 mg BID over 12 weeks (Shoptaw et al., 2006) \[[@CR61]\]*n* = 229, MA-dependent4-arm, sertraline + CM, sertraline only, PB + CM, PB only, outpatient, USASertraline inferior to PB (UDS), more AEs, sertraline participants more likely to terminate treatment early Atomoxetine80 mg OD over 16 weeks (Schottenfeld et al., 2018) \[[@CR58]\]*n* = 69, male, ATS and opioid dependent, ATS use \> 2 days/week in past month, positive UDS for both substancesDB, PB, analysed as ITT, manual-based behavioural counselling, all participants received buprenorphine and naloxone as part of treatment, inpatient then outpatient, MalaysiaSmall reduction in ATS use in atomoxetine arm (UDS). Depression reduced in treatment arm (CES-D). Opioid use reduced in PB arm (UDS). No change in abstinence (UDS)Tricyclic antidepressants (TCAs) Imipramine150 mg OD over up to 180 days (Galloway et al., 1994) \[[@CR36]\]*n* = 183, MA or cocaine dependentDB, low-dose imipramine control, analysed as ITT, group counselling, outpatient, USAHigher dose imipramine associated with improved treatment retention. No difference in MA use, craving, depression (UDS, VAS, BDI)Atypical antipsychotics Aripiprazole20 mg OD over 12 weeks (Coffin et al., 2013) \[[@CR28]\]*n* = 90, MA-dependent, treatment seeking, positive MA UDSDB, PB, analysed as ITT, CBT and MI, outpatient, USANo difference in use (UDS), no difference in adherence, sexual risk behaviours, craving, depression (MEMS, standard criteria, VAS, CES-D)5--10 mg OD over 2 weeks (open label) then 8 weeks (randomised) (Sulaiman et al., 2013) \[[@CR62]\]*n* = 37, MA-dependent, MA use more than once a week for the past 3 months, has a history of psychosisDB, PB, analysed as ITT, outpatient, MalaysiaNo difference in abstinence (UDS), treatment arm retained longer and had improved craving (BSCS). Reduced psychotic symptoms (PANSS) Aripiprazole and methylphenidate15 mg OD, 54 mg OD over 20 weeks (Tiihonen et al., 2007) \[[@CR64]\]*n* = 53, AMPH or MA-dependent, people who inject drugs3-arm, aripiprazole vs methylphenidate vs PB, DB, analysed as ITT, outpatient, FinlandAripiprazole inferior, more positive UDS than methylphenidate and PB (UDS). Methylphenidate may reduce use (UDS). Study stopped early due to aripiprazole inferiority and AEsAnticonvulsants Topiramate200 mg OD over 13 weeks (Elkashef et al., 2012) \[[@CR32]\]*n* = 140, MA-dependent, positive UDSDB, PB, analysed as ITT, BBCET, outpatient, USANo difference in abstinence (UDS), may facilitate reduction in MA use and severity of dependence (UDS, CGI-O, CGI-S). No difference in depression, craving, anxiety (MADRS, BSCS, ASI)200 mg OD over 10 weeks (Rezaei et al., 2016) \[[@CR55]\]*n* = 62, MA dependent, positive UDSDB, PB, completer analysis, outpatients, IranNo difference in use (UDS), reduced severity/need (ASI). No difference in craving or depression (BSCS, BDRS)Central nervous system stimulants Dexamphetamine30 mg (SR) BID over 8 weeks (Galloway et al., 2011) \[[@CR35]\]*n* = 60 MA-dependent, treatment seeking, positive UDSDB, PB, analysed as ITT, MET, outpatient, USANo difference in MA use (UDS), significantly improved withdrawal and craving scores (AWQ, desires for speed questionnaire, VAS)110 mg (SR) OD over 16 weeks (Longo et al., 2010) \[[@CR50]\]*n* = 49, MA-dependent, positive UDS, use \> 3 times per week for past 12 monthsDB, PB, analysed as ITT, CBT, outpatient clinic for initial stabilisation, then through community pharmacies, AUSTreatment arm retained in care longer, no differences in use (UDS, hair analysis, self-report). Reduced withdrawal symptoms in treatment arm during stabilisation period (AWQ). At follow-up, reduced dependence in treatment arm (LDQ) Methylphenidate54 mg OD over 14 weeks (Ling et al., 2014) \[[@CR48]\]*n* = 110, MA-dependentDB, PB, analysed as ITT, CBT and CM, outpatient, USANo difference in use at any time point; however, change in use larger in treatment arm (self-report). No difference in use by UDS. Craving higher in PB by CCQ-now, no difference by VAS54 mg OD over 22 weeks (Miles et al., 2013) \[[@CR51]\]*n* = 79, MA- or AMPH-dependent, positive UDSDB, PB, analysed as ITT, standard care therapy in addition to protocol, outpatient, New Zealand and FinlandNo difference in weekly abstinence (UDS). Treatment arm may improve retention. No differences in craving, dependence, medication adherence (VAS, SDS, pill count)54 mg OD over 10 weeks (Rezaei et al., 2015) \[[@CR54]\]*n* = 56, MA-dependent, positive UDSDB, PB, analysed as ITT, no psychotherapy, outpatient, IranReduced craving at endpoint only (VAS). Use and depressive symptoms reduced at end point (UDS, BDI-II). No difference in dependence, adherence (ASI, pill count)Other central nervous system agents Modafinil200 mg OD and 400 mg OD over 12 weeks (Anderson et al., 2012) \[[@CR25]\]*n* = 210, MA-dependent, positive UDS3-arm, 200 mg vs 400 mg vs PB. DB, analysed as ITT, Matrix CBT, MET, outpatient, USANo difference in treatment effectiveness by weekly abstinence (UDS). No differences in use, dependence, self-control, ADHD symptoms, HIV risk, impulsiveness (UDS, ASO, CGI-O, CGI-S, BSCS, HRBS, HAM-D, Barratt's Impulsiveness Scale)400 mg OD over 12 weeks (Heinzerling et al., 2010) \[[@CR38]\]*n* = 71, MA-dependent, treatment seekingDB, PB, analysed as ITT, CBT and CM, outpatient, USANo difference in use (UDS). No difference in treatment retention, craving, depression, cigarette smoking (VAS, BDI, self-report)200 mg OD over 7 days (Lee et al., 2013) \[[@CR47]\]*n* = 20, MA-dependent, last use within 48 hDB, PB, analysed as ITT, no psychotherapy, residential units, AUSNo difference in retention in care or withdrawal symptoms (AWQ, ACSA, ASSA).No difference in craving, sleep or physiological measures (VAS, St. Mary's Hospital Sleep Questionnaire, heart rate, blood pressure, respiratory rate)200 mg OD over 10 weeks (Shearer et al., 2009) \[[@CR59]\]*n* = 80, MA-dependent, use 2--3 days per week, positive UDSDB, PB, analysed as ITT, CBT, outpatient, AUSNo difference in retention or medication adherence (count, MEMS cap). No difference in use, craving, dependence (UDS, OTI, self-report, BSI, VAS, SDS)GABA~B~ agonist/GABAergic agents Baclofen and gabapentin20 mg, 800 mg TID over 16 weeks (Heinzerling et al., 2006) \[[@CR40]\]*n* = 88, MA-dependent3-arm, baclofen vs gabapentin vs PB. DB, analysed as ITT, relapse prevention group therapy, outpatient, USANo difference between arms for MA use (UDS). No difference in retention, depression or craving scores (BDI, VAS)Opioid agonists Buprenorphine6 mg OD over 16 weeks (Salehi et al., 2015) \[[@CR57]\]*n* = 40, 18- to 40-year-old men, MA-dependent, referred to treatment centreDB, PB, analysis not clear, Matrix Model and self-help group, inpatient, IranCraving reduced in treatment arm; however, difference disappeared once medication was stopped (CCQ-Brief). Abstinence improved in treatment arm, but difference disappeared at follow-up (UDS) Buprenorphine and methadone8 mg, 40 mg OD over 17 days (Ahmadi et al., 2017) \[[@CR24]\]*n* = 40, MA-dependent, daily use for past 6 months, abstinent at start of trialDB, two treatment arms, no control, analysed as ITT, no psychotherapy, inpatient, IranCraving reduced in both arms, significantly more in buprenorphine on days 10--14 (out of 17) only (VAS). All participants completed trial, no positive UDS recorded. No control group makes inference difficultOpioid antagonist Naltrexone380 mg (XR) intramuscular injection, 4-weekly over 12 weeks (Coffin et al., 2018) \[[@CR29]\]*n* = 100, MA-dependent, men (or identifying male), anal sex with men while under the influence of MA in the past 6 months, positive UDSDB, PB, analysed as ITT, CBT and MI, outpatient USANo difference in MA use (UDS). No difference in adherence, sexual risk behaviours, craving or depression (Audio Computer-Assisted Self-Interviewing, VAS, SDS, CES-D, PHQ2)50 mg OD over 12 weeks (Jayaram-Lindström et al., 2008) \[[@CR42]\]*n* = 80, AMPH-dependent, used AMPH on at least 12 days in past 12 weeksDB, PB, analysed as ITT, relapse prevention therapy, outpatient, SwedenAbstinence higher in treatment arm (UDS). APMH use (self-report), and craving (VAS) also reduced in treatment arm. No difference in severity of dependence (ASI)380 mg (XR) over 4 weeks intramuscular injection, single monthly dose (Kohno et al., 2018) \[[@CR45]\]*n* = 52, MA-dependent, right-handed, abstinent from all drugs \> 72 hDB, PB, completer analysis, no psychotherapy, outpatient, USAReduced use in treatment arm (self-report), no difference in craving (VAS). Use/craving were both secondary outcomes380 mg (XR) intramuscular injection, monthly over 24 weeks (Runarsdottir et al., 2017) \[[@CR56]\]*n* = 100, AMPH-dependent, use \> 10 days in past 31, complete 7- to 10-day inpatient detox and abstinent at start of trialNB, PB, analysed as ITT, MI, CBT (group and individual), post-detox, outpatient, IcelandNo difference in abstinence (UDS). No difference in adherence, retention, other drug use, cravings or relapse rate (pill count, timeline follow back, UDS, VAS, ASI)1000 mg (implant) once (subcutaneous) over 10 weeks (Tiihonen et al., 2012) \[[@CR63]\]*n* = 100, AMPH and opioid dependent \> 1-year duration, negative UDS, relative (support person) willing to participate and stable home address/phone numberDB, PB, analysed as ITT, no psychotherapy, outpatient, RussiaNaltrexone arm retained in care longer, reduced overall (AMPH and opioid as aggregate) use (UDS), greater treatment effect (CGI). However, when just examining AMPH use, no difference in use (UDS) and no difference in craving (VAS)5HT~3~-receptor antagonist Ondansetron0.25 mg, 1 mg, 4 mg BID over 8 weeks (Johnson et al., 2008) \[[@CR44]\]*n* = 150, MA-dependent, treatment seeking, positive UDS4-arm study, 0.25 mg vs 1 mg vs 4 mg vs PB. DB, analysed as ITT, group CBT, outpatient, USANo differences in abstinence, use, non-use days or 3-week abstinence were detected between groups (UDS). No differences in measures of dependence, withdrawal, craving, retention in care (CGI-O, CGI-S, ASI-Lite, MAWQ, BSCS)Partial cholinergic nicotinic agonist Varenicline1 mg BID over 9 weeks (Briones et al., 2018) \[[@CR27]\]*n* = 52, MA-dependent, treatment seeking, positive UDSDB, PB, analysed as ITT, CBT, inpatient then outpatient, USANo difference in EOTA or TES (UDS). No difference in time-to-relapse (UDS); however, treatment arm reported less cigarette smoking (cigarette count)Glutamatergic agents N-acetyl cysteine (NAC)1200 mg OD over 8 weeks (Mousavi et al., 2015) \[[@CR53]\]*n* = 32, MA-dependentCrossover design, DB, PB, analysis not clear, Matrix Model CBT, psychiatric clinic/psychiatric emergency department, IranReduced craving associated with NAC (CCQ-Brief). Study did not report secondary outcome results N-acetyl cysteine (NAC) and naltrexone2400 mg, 200 mg OD over 8 weeks (Grant et al. 2010) \[[@CR37]\]*n* = 31, AMPH-dependent, MA primary AMPH usedDB, PB, analysed as ITT, no psychotherapy, outpatient, USANo difference in craving or use between arms (Penn Craving Scale, UDS). No difference in global state, dependence, depression, anxiety or quality of life (CGI-S, HAM-D, HAM-A, SDS, Quality of Life Index) Riluzole50 mg BID over 12 weeks (Farahzadi et al., 2019) \[[@CR34]\]*n* = 86, MA-dependentDB, PB, analysed as ITT, Matrix Model CBT, outpatient, IranTreatment arm reported higher EOTA (UDS). Treatment associated with improvement in dependence scores, withdrawal, craving, depression (ASSA, AWQ, Stimulant Craving Questionnaire, VAS, HAM-D)CRF1 antagonist Pexacerfont300 mg OD over 3 weeks (Morabbi et al., 2018) \[[@CR52]\]*n* = 51, men, AMPH or opioid dependentTapering dose over 3 weeks, DB, PB, analysed as ITT, no psychotherapy, residential camps, IranCraving was reduced in the treatment group (VAS), no difference in EOTA (UDS). Temptation and depression scales were improved in treatment arm (Beck Depression, VAS), no differences in treatment effectiveness, withdrawal or anxiety (UDS, AWQ, Beck Anxiety). Did not present findings for AMPH only, all in aggregate with opioidsBenzodiazepine antagonist/GABA agonist/H1 histamine receptor Flumazenil, gabapentin and hydroxyzine2 mg, 1200 mg, 50 mg per protocol over 40 days (Ling et al., 2012) \[[@CR49]\]*n* = 120, MA-dependent, treatment seeking, MA use \> 4 days in the past 30DB, PB, analysed as ITT, CBT, inpatients and outpatients, USANo difference in rates of abstinence (UDS). No difference in craving, use, retention (BSCS, ASI, UDS)2 mg, 1200 mg, 50 mg per protocol over 30 days (Urschel et al., 2011) \[[@CR65]\]*n* = 135, MA-dependent, treatment seeking, last use within 3 daysDB, PB, analysed as ITT, Matrix Model CBT, CM, outpatients, USATreatment arm reported reduced craving scores (VAS). No difference in use by UDS (imputing missed doses as positive), reduced use in treatment arm by self-report; conflicts with Ling, 2011; however, this study included CM and Ling, 2011 did not*ACSA* Amphetamine Cessation Symptoms Assessment, *ADHD* attention-deficit hyperactivity disorder, *AE* adverse event, *AMPH* amphetamine, *ASI* Addiction Severity Index, *ASI*-*Lite* Addiction Severity Index-Lite, *ASI*-*5* Addiction Severity Index-5th edition, *ASSA* Amphetamine Selective Severity Assessment, *ATS* amphetamine-type substance, *AUS* Australia, *AWQ* Amphetamine Withdrawal Questionnaire, *BBCET* Brief Behavioural Compliance Enhancement Therapy, *BDI* Beck Depression Inventory, *BDI*-*II* Beck Depression Index-Version 2, *BDRS* Bipolar Depression Rating Scale, *BID* twice daily, *BSCS* Brief Self-Control Scale, *BSI* Brief Symptom Inventory, *CBT* cognitive behavioural therapy, *CCQ*-*BRIEF* Cocaine Craving Questionnaire-Brief, *CCQ*-*Now* Cocaine Craving Questionnaire-Now, *CES*-*D* Centre for Epidemiological Studies depression scale, *CGI*-*O* Clinical Global Impression-Observer, *CGI*-*S* Clinical Global Impression-Self, *CM* contingency management, *CO* carbon monoxide, *DASS* Depression Anxiety Stress Score, *DB* double-blind, *EOTA* end-of-treatment abstinence, *HAM*-*A* Hamilton Anxiety Scale, *HAM*-*D* Hamilton Depression Scale, *HIV* human immunodeficiency virus, *HRBS* Health-Related Behaviours Survey, *ITT* Intention-to-treat, *LDQ* Leeds Depression Questionnaire, *MA* methamphetamine, *MADRS* Montgomery--Åsberg Depression Rating Scale, *MAWQ* Methamphetamine Withdrawal Questionnaire, *MEMS* Medication Event Monitoring System, *MET* motivational enhancement therapy, *MI* motivational interviewing, *MSM* men who have sex with men, *NAC* N-acetyl cysteine, *NB* not blinded, *OD* once daily, *OTI* Opioid Treatment Index, *PANSS* Positive and Negative Syndrome Scale, *PB* placebo-controlled, *PHQ2* Patient Health Questionnaire-2, *QECCR* Questionnaire for Evaluating Cocaine Craving and related Responses, *SDS* Severity of Dependence Scale, *SR* sustained-release, *SUD* substance use disorder, *TES* Treatment Effectiveness Score, *TID* three times daily, *UDS* urine drug screen, *VAS* Visual Analogue Scale, *XR* extended release

Risk of Bias Within and Across Studies {#Sec5}
--------------------------------------

Risk of bias in individual study methods and reporting are included in Supplementary Table 1 and Supplementary Data (see ESM) as considerations across a number of domains. Across all studies, allocation of participants was by random assignment, and all but three studies \[[@CR46], [@CR56], [@CR66]\] were double-blind. Study completion rates were low, with studies reporting the proportion of the sample who did not complete the protocol as 38.4% of the total randomised. Eighty-three percent of studies analysed their results by intention-to-treat, while five (12%) \[[@CR33], [@CR46], [@CR53], [@CR57], [@CR61]\] were unclear in this regard and two (5%) \[[@CR24], [@CR45]\] did not. Females were underrepresented in the data, being only 29.7% of the total participants. This comprises both studies that only enrolled males (nine studies, 21%) \[[@CR24], [@CR29], [@CR30], [@CR34], [@CR46], [@CR52], [@CR55], [@CR57], [@CR58]\] and those enrolling both males and females but with higher male enrolments. Thirty-four (79.1%) of the studies we reviewed excluded participants with depression or psychotic disorders, or those taking an antidepressant or antipsychotic medication.

Some authors overstated conclusions; for example, recommending treatment uptake despite limited sample sizes, lack of placebo and/or low completion rates. The studies were overwhelmingly government or academic funded (65.1%, *n* = 28) \[[@CR24]--[@CR28], [@CR30], [@CR32], [@CR33], [@CR35]--[@CR42], [@CR44], [@CR47], [@CR50], [@CR51], [@CR54], [@CR55], [@CR57], [@CR58], [@CR60], [@CR63], [@CR64], [@CR66]\]. Ten studies (23.3%) were funded by pharmaceutical companies, or the study drug(s) were provided by a pharmaceutical company, or a mix of funding and drugs were provided by a pharmaceutical company \[[@CR29], [@CR31], [@CR45], [@CR46], [@CR48], [@CR49], [@CR56], [@CR59], [@CR61], [@CR65]\]. Four studies (9.3%) did not state their funding source \[[@CR43], [@CR52], [@CR53], [@CR62]\], and one study (2.3%) received no funding \[[@CR34]\].

Outcomes and Measures {#Sec6}
---------------------

In total, 55 primary outcome measures were used (inclusive of variations) 93 times (as some studies had multiple primary outcomes). The most common primary outcome measure reported was abstinence (51 times, 55%), followed by cravings (10 times, 11%). For abstinence, urine drug screens (UDS) were used 41 times (80%) and analysed or defined in 16 different ways. The most common method for analysing UDS was weekly proportion of AMPH/MA-free UDS, or overall proportion of AMPH/MA-free UDS. There were 75 distinct secondary outcomes inclusive of variations and often analysed differently to the primary outcomes of the same domain. These were used 158 times. The most common secondary outcome measure reported was craving (25 times), predominantly reported using the visual analogue scale (VAS) (16 times, 64% of the cravings measures). The frequency with which each measure was used is noted in Table [5](#Tab5){ref-type="table"}.Table 5Outcomes and measuresOutcome assessedMeasures usedVariations on analysisPrimary outcomes Abstinence (from AMPH, MA, or amphetamine-type substance \[ATS\]) (*n* = 51)Urine drug screen (UDS) (*n* = 41)Variations in cut-off points and measures:  • 1000 ng/mL (*n* = 1)  • 300 ng/mL (*n* = 2)  • Confirmed by mass spectrometry    -- 78 ng/ml (*n* = 1)    -- \< 300 ng/mL (*n* = 1)Comparing proportion of participants in each group demonstrating abstinence in the final 2 weeks of study---abstinence defined by having all UDS test negative and providing *at least two* UDS per week (*n* = 1)Comparing proportion of participants in each group demonstrating abstinence in the final 2 weeks of study---abstinence defined by having all UDS test negative and providing *all* UDS in final 2 weeks of study (*n* = 3)Negative UDS during final 2 weeks of treatment and *no more than* 1 of 3 possible UDS missing per week (*n* = 2)Weekly proportion of negative UDS (or weekly proportion of positive UDS) (*n* = 5)Proportion of UDS testing negative during the study (*n* = 5)Treatment Effectiveness Score (TES):  • the sum of the number of negative (AMPH, MA, ATS) UDS during the treatment phase per participant (*n* = 3)  • average of the sum of negative UDS submitted per participant in each treatment arm (*n* = 1)Joint Probability Index: number of negative (AMPH, MA, ATS) UDS submitted by each participant in each treatment group at time point (end-of-treatment or follow-up visit) divided by the number of participants randomised to that treatment group (*n* = 3)Longest period of uninterrupted abstinence (*n* = 3)Percentage of participants with at least  • 2 weeks' abstinence (*n* = 2)  • 3 weeks' abstinence (*n* = 3)Drug 'free' week: A week in which all non-missing urine samples in the week (3 samples/week) were drug free (AMPH, MA, ATS) (*n* = 1)Negative 'use week' (*n* = 1)UDS collected 3 times per week: 'use week' defined as each 7-day period beginning with first dose of study drug  • A 'positive use week' was any week in which ≥ 1 UDS was MA-positive  • A 'negative use week' was any week in which all UDS were MA-negative, even if only 1--2 UDS were collected  • Data were considered missing if 0 UDS were collectedSelf-report (*n* = 4)Abstinence for 21 days any time during the study period (*n* = 2)Days per week (e.g. self-reported non-use days) (*n* = 1)Frequency of use in prior 2 weeks (AMPH, MA, ATS) (*n* = 1)Drug diaries  • 28 days prospective (*n* = 1)Timeline Follow Back (TLFB) (*n* = 2)Opiate Treatment Index (OTI) (*n* = 1)  • For self-reported MA use substituted for opiatesHair analysis (*n* = 1) Changed use/reduction in use (*n* = 7)Reduction in UDS-positive metabolites (*n* = 3)Decrease in average weekly log10 median urine MA concentrations over treatment periodOverall change in proportion of positive UDS(AMPH, MA, ATS) (*n* = 3)  • Over study period (*n* = 2)  • Per week (*n* = 1)New MA use (*n* = 1)Determined by MA-positive first sample; following sample with no MA; MA detected in subsequent sample; following sample with MA detected; MA detected in subsequent sample in greater quantities than would be expected on the basis of mean half-life plus 2 standard deviations (SD); participant self-reports new use of MA since prior sample Treatment efficacy (*n* = 3)UDS (*n* = 3)  • Number of non-use weeks (*n* = 1)  • Number of negative UDS during treatment (*n* = 1)  • Number of abstinence events (*n* = 1)Amphetamine Withdrawal Questionnaire (AWQ) (*n* = 1) Craving (*n* = 10)Visual analogue scales (VAS) (*n* = 5)  • 10 mm (point) VAS (*n* = 1)  • 100 mm (point) VAS (*n* = 1)Brief Substance Craving Scale (BSCS) (*n* = 1)Questionnaire for Evaluating Cocaine Craving and Related Responses (QECCRR) (*n* = 1)Cocaine Craving Questionnaire---Brief (CCQ-B) (*n* = 2)Penn Craving Scale (*n* = 1) Withdrawal (*n* = 3)AWQ (*n* = 1)Amphetamine Cessation Symptoms Assessment (ACSA) (*n* = 1)Amphetamine Selective Severity Assessment (ASSA) (*n* = 1) Dependence (*n* = 3)Leeds Dependence Questionnaire (LDQ) (*n* = 1)Addiction Severity Index (ASI)/ASI-Lite (*n* = 1)Severity of Dependence Scale (SDS) (*n* = 1) Depression (*n* = 1)Beck Depression Inventory (BDI) (*n* = 1)Psychopathology (*n* = 1)Brief Symptom Inventory (BSI) (*n* = 1) Clinical Impression (*n* = 1)Clinical Global Impression Scale (CGI) (*n* = 1) Retention in treatment/study (*n* = 5)  • Average duration of time in care (*n* = 3)  • Number of participants who complete treatment (*n* = 2) Participant satisfaction (*n* = 3)  • Type and number of adverse events (AEs) (*n* = 3) Feasibility (*n* = 2)  • Feasibility to recruit (*n* = 1)  • Tolerability of study drug (*n* = 1) Adherence (*n* = 3)Pharmacy records (*n* = 1)Medication Event Monitoring System (MEMS) caps (*n* = 1)Study drug metabolites in urine (*n* = 1)Secondary outcomes Abstinence (from AMPH, MA, or ATS) (*n* = 22)UDS (*n* = 10)Comparing proportion of participants in each group demonstrating abstinence in the final 2 weeks of study---abstinence defined by having all UDS test negative and providing *at least two* UDS per week (*n* = 2)Weekly proportion of negative UDS (or weekly proportion of positive UDS) (*n* = 2)Proportion of UDS testing negative during the study (*n* = 2)Treatment Effectiveness Score (TES):  • average of the sum of negative UDS submitted per participant in each treatment arm (*n* = 1)Self-reportAbstinence for 21 days any time during the study period (*n* = 1)Days since last use (*n* = 1)Days per week (e.g. self-reported use or non-use days) (*n* = 4)Frequency of use in prior 2 weeks (AMPH, MA, ATS) (*n* = 1)Drug-free days (*n* = 1)TLFB (*n* = 3)OTI (*n* = 1)  • Drug use subscale Changed use/reduction in use (*n* = 4)Decrease in average weekly log10 median urine MA concentrations over treatment period (*n* = 2)Time to relapse (*n* = 2)  • Amongst those who previously achieved abstinence (*n* = 1)  • Relapse for participants with negative MA UDS at baseline (*n* = 1) Craving (*n* = 25)VAS (*n* = 16)  • 7 mm (point) VAS (*n* = 1)  • 100 mm (point) VAS (*n* = 5)BSCS (*n* = 6)Stimulant Craving Questionnaire (STCQ) (*n* = 1)'Desires for Speed' modification of 'Desires for Alcohol' Questionnaire (*n* = 1)Craving Questionnaire---Now version (CQ-Now) (*n* = 1) Withdrawal (*n* = 5)AWQ (*n* = 3)ACSA (*n* = 1)Methamphetamine Withdrawal Questionnaire (MAWQ) (*n* = 1) Dependence (*n* = 14)ASI/ASI-Lite (*n* = 10)SDS (*n* = 3)ASSA (*n* = 1) Depression (*n* = 20)BDI (*n* = 8)Montgomery-Åsberg Depression Rating Scale (*n* = 2)Centre for Epidemiologic Studies Depression Scale (CES-D) (*n* = 4)Hamilton Depression Rating Scale (HAM-D) (*n* = 4)Depression Anxiety Stress Scale (DASS) (*n* = 1)  • Full scale and sub-scoresBeck Depression Inventory II (BDI-II) (*n* = 1) Anxiety (*n* = 3)Hamilton Rating Scale for Anxiety (HAM-A) (*n* = 1)Beck Anxiety Inventory (*n* = 1)Anxiety State Index (*n* = 1) Psychological distress (*n* = 1)Patient Health Questionnaire-2 (PHQ-2) (*n* = 1) Psychopathology (*n* = 2)BSI (*n* = 1)Positive and Negative Symptoms Scale (PANSS) (*n* = 1) Clinical impression (*n* = 9)Clinical Global Impression Scales: Observer (CGI-O) (*n* = 3)Clinical Global Impression Scales: Self (CGI-S) (*n* = 4) Retention in treatment/study (*n* = 11)  • Days admitted as inpatient (*n* = 3)  • Number of days received study drugs following first dose (*n* = 1)  • Number of days attended from randomisation to the final study visit (*n* = 1)  • Provision of at least one UDS during Week 8 of study (*n* = 1)  • Days between first study drug infusion and last clinic visit (*n* = 1)  • Study drug doses collected (*n* = 1)  • Number of treatment days during outpatient treatment until the last clinical contact (*n* = 3) Participant satisfaction (*n* = 1)  • Percentage of participants completing active medication, mean number weeks in treatment (n = 1)Adherence (*n* = 13)Self-report using AIDS Clinical Trials Group Questionnaire (ACTG) (*n* = 1)Pill count (*n* = 7)MEMS caps (*n* = 2)Study drug metabolites in urine (*n* = 2)Dose logs (*n* = 1) Risk behaviour (*n* = 4)HIV Risk-Taking Behaviour Scale (HRBS) (*n* = 1)HIV Risk Assessment Battery (*n* = 1)Audio Computer-Assisted Interview (ACASI) for self-report (*n* = 2)  • Number male partners  • Number male partners with whom MA used  • Episodes anal sex (insertive/receptive) with HIV serodiscordant partners  • Drug use  • Substance use treatment  • Sexual risk behaviour Attention-deficit hyperactivity disorder (ADHD) (*n* = 3)Adult ADHD Clinical Diagnostic Scale (ACDS) (*n* = 1)Adult ADHD Investigator Symptom Rating Scale (AISRS) (*n* = 1)Barratt Impulsiveness Scale (*n* = 1) Neuro-cognition (*n* = 1)Cambridge Neuropsychological Test Automated Battery (CANTAB) (*n* = 1) Safety (*n* = 7)Serious adverse events (SAEs)/adverse events (AEs) (*n* = 3)Physiological indicators (*n* = 4)  • Vital statistics (*n* = 3)  • Electrocardiogram (ECG) results (*n* = 1) Quality of life (*n* = 3)The Quality of Life Inventory (QoLI) (*n* = 1)Euro-QoL (*n* = 1)Global Assessment of Functioning (GAF) score (*n* = 1) Disability (*n* = 1)Sheehan Disability Scale (*n* = 1) Sleep (*n* = 2)Athens Insomnia Scale (AIS-5) (*n* = 1)St Mary's Hospital Sleep Questionnaire (*n* = 1) Other substance use (*n* = 3)Cigarettes (*n* = 3)  • Weekly number cigarettes in smoker subgroup (*n* = 2)  • Carbon monoxide tests (*n* = 1) Other adverse effects (*n* = 4)Liver function tests (LFTs) (*n* = 1)Abnormal Involuntary Movement Scale (AIMS) (*n* = 1)Barnes Akathisia Scale (BAS) (*n* = 1)Simpson Angus Scale (SAS) (*n* = 1)*AMPH* amphetamine, *HIV* human immunodeficiency virus, *MA* methamphetamine

Adherence as an outcome was measured by participant self-report; pill count (i.e. total pills taken divided by total prescribed multiplied by 100 to provide a percentage of adherence); medication electronic monitoring systems (MEMS, e.g. an electronic monitor in bottle caps); proportion of study staff-administered doses received; or measures of metabolites/study drug in plasma. Eleven studies (25.6%) did not report adherence in methods/results. In studies reporting both self-report and another measure, there was low concordance between results. For example, in one study self-reported adherence was 93% but ad-hoc analysis of study drug/metabolite in urine results of participants randomised to the study drug group were presented in quartiles, with the top quartile achieving \> 85% positive urines while the bottom quartile showed ≤ 40% positive urines \[[@CR25]\]. Adherence reported by both self-report and MEMS caps demonstrated non-concordance in the two studies reporting both---one study reported adherence assessed by MEMS caps was 42% as compared with 74% by self-report \[[@CR28]\], another reported 48.5% versus 74.7% \[[@CR30]\]. No study reporting plasma metabolite/study drug reported a marker of adherence for placebo. Adherence rates ranged from 21% \[[@CR51]\] to 100% \[[@CR55]\] across studies. Full data for each study are available in the Supplementary Data (see ESM).

Results of Individual Studies {#Sec7}
-----------------------------

### Antidepressants {#Sec8}

One study (2%) examined amineptine \[300 mg oral (po) daily (OD)\], an atypical tricyclic antidepressant, in inpatient participants for AMPH withdrawal over 14 days \[[@CR43]\]. Participants randomised to amineptine were significantly less depressed at Day 7 and had improved clinical global impression scores at Day 14 in the completer analysis (i.e. only those completing study protocol) compared with placebo. However, the sample size was small (29 analysed). In terms of feasibility, amineptine has never been approved by the US Federal Drug Administration (FDA) and has been suspended in other jurisdictions due to hepatotoxic effects and abuse liability.

Mirtazapine was examined in three studies (7%). Mirtazapine's effects on withdrawal symptoms were reported on twice, yielding conflicting results. In a 2005 study examining mirtazapine (15--60 mg po OD) in AMPH withdrawal \[[@CR46]\], Amphetamine Withdrawal Questionnaire (AWQ) \[[@CR67]\] scores between baseline and Days 3 and 14 demonstrated significant differences favouring mirtazapine over placebo, but the study only enrolled 20 participants and the number analysed was unclear. In contrast, with a primary outcome of retention, a 2008 study of mirtazapine (30 mg po OD) for the treatment of MA withdrawal \[[@CR31]\] demonstrated no difference in retention rates, or the secondary outcome of MA withdrawal symptoms. The third study \[[@CR30]\] aimed to reduce MA use among MA-dependent sexually active men who have sex with men. The proportion of MA-positive UDS was significantly reduced in both study arms over time but was more pronounced and quicker in the mirtazapine (30 mg po OD) arm compared with the control arm. Participants randomised to the mirtazapine arm also reduced their high-risk sexual behaviours (based on a questionnaire), leading the authors to conclude that mirtazapine decreased both MA use and high-risk sexual behaviours in this population, despite fairly low adherence rates by MEMS caps and self-report (\< 50%).

Bupropion was examined in six studies (14%) \[[@CR26], [@CR33], [@CR39], [@CR41], [@CR60], [@CR66]\]; four reported on AMPH/MA abstinence as the primary outcome, and two on reduction of AMPH/MA use. None of the six studies achieved a statistically significant difference in abstinence or reduction in use between the bupropion and placebo arm in planned primary outcome analyses.

In one study \[[@CR60]\], a post hoc analysis found a statistically significant effect for bupropion (150 mg po twice daily \[BD\]) as compared with placebo when the sample was stratified by 'baseline light-MA consumers' (0--2 MA-positive UDS in 2-week baseline period) versus 'baseline-heavy MA consumers' (3--6 MA-positive UDS in 2-week baseline period). Among 'baseline light-MA consumers', the probability of achieving an MA-free week was significantly higher in the bupropion arm as compared with placebo (odds ratio \[OR\] of 2.8, *p* \< 0.0001), but there was no statistically significant difference between bupropion and placebo in 'baseline-heavy MA consumers'. A similar planned sub-group analysis in another study of bupropion (150 mg po BD) for the treatment of MA dependence \[[@CR33]\] demonstrated that the sub-group of participants with ≤ 18 days' MA use in the 30 days prior to baseline who were randomised to bupropion had an increase in weekly periods of MA abstinence as compared with placebo. In additional subgroup analysis, the male-only participants randomised to bupropion also demonstrated a higher proportion of MA-free weeks as compared to placebo \[[@CR33]\]. Further analysis determined that two subgroups were significantly more likely to have an MA-free week: male participants with low baseline use (OR 1.39 and OR 1.34; *p* ≤ 0.001) who were randomised to bupropion; and non-depressed female participants with low baseline use (OR 1.27; *p* = 0.02) who were randomised to bupropion.

Given bupropion's licensed indication as a smoking cessation aid, unsurprisingly in one study examining the effects of bupropion on both smoking and stimulant use, participants randomised to bupropion were more likely to reduce their smoking compared with placebo \[[@CR66]\].

One study (2%) examined sertraline (50 mg po BD), along with CM for the treatment of MA dependence over 14 weeks \[[@CR61]\]. The four study arms were sertraline only, sertraline and CM, placebo only, placebo and CM. There was no statistically significant main or interaction effect of either sertraline or CM for measures of MA use. In fact, those in the sertraline-only arm were significantly less likely to achieve 3-week abstinence and significantly more likely to have an MA-positive UDS throughout the study compared with other study arms.

One study examined imipramine (150 mg po OD) for the treatment of cocaine and MA dependence \[[@CR36]\]. The primary outcome was retention in care, and the survival analysis indicated that higher doses of imipramine were associated with enhanced retention in treatment which in turn was associated with more frequent clinical contacts. There were no statistically significant differences between arms on secondary outcomes of time since last MA use, cravings or depression. Notably, 32 of the 183 participants (17.4%) were MA dependent, the rest were cocaine dependent. This study was not placebo controlled, control participants were provided with a reduced dose of imipramine (10 mg versus 150 mg daily), primarily to increase blinding efficacy and acceptability by staff and participants.

A study of atomoxetine (80 mg po OD), a selective norepinephrine (noradrenaline) reuptake inhibitor (SNRI), randomised 69 opioid and ATS-dependent participants to 16 weeks of treatment, assessing ATS use as the primary outcome \[[@CR58]\]. The proportion of ATS-negative UDS was higher in the atomoxetine arm compared with placebo, but achieved only a small effect size, while there was no statistically significant difference in days abstinent. For secondary outcomes, the proportion of morphine-negative UDS was lower for the atomoxetine arm, while the depression scores were significantly reduced in the atomoxetine arm compared with placebo \[[@CR58]\].

### Atypical Antipsychotics {#Sec9}

Aripiprazole was assessed in two studies on its own \[[@CR28], [@CR62]\], and once in a study that also had a second active agent arm---methylphenidate \[[@CR64]\]. Aripiprazole (20 mg po OD) for the treatment of MA dependence was no more effective than placebo in reducing MA consumption or reduction in MA-positive UDS \[[@CR28]\]. In another study of the treatment of MA dependence and associated psychoses, participants randomised to aripiprazole (5--10 mg po OD) demonstrated no significant difference in abstinence compared with placebo \[[@CR62]\]. However, those randomised to the aripiprazole arm were more likely to be retained in treatment, and to demonstrate a decrease on symptom scores for psychopathology on the Positive and Negative Symptoms Scale (PANSS) \[[@CR62]\].

A study investigating aripiprazole versus methylphenidate for AMPH dependence (primary outcome AMPH use, secondary outcomes change in use and retention) enrolled three study arms: aripiprazole 15 mg daily, methylphenidate 54 mg daily or placebo \[[@CR64]\]. The aripiprazole study arm had significantly more AMPH-positive UDS compared with either the methylphenidate or placebo arms. The study was ceased early due to this finding at interim analysis. The analysis also demonstrated that participants randomised to the methylphenidate arm returned significantly fewer AMPH-positive UDS than placebo. In addition, two participants (4% of randomised participants) in the aripiprazole arm discontinued the study due to adverse events.

### Anticonvulsants {#Sec10}

Topiramate was investigated in two studies reviewed here. One study examined topiramate (200 mg po OD) in MA-dependent adults (*n* = 140 randomised, 77 completed study) with the primary outcome being MA abstinence at Week 12 \[[@CR32]\]. While there was no statistically significant difference between topiramate and placebo on the primary outcome, a higher proportion of participants randomised to topiramate reduced their MA use compared with placebo.

In a separate study, topiramate (200 mg po OD) for MA dependence was examined in 62 males and analysed in 57, who were all on prescribed methadone for opiate replacement therapy \[[@CR55]\], with the outcomes of interest being dependence severity, cravings, depression and MA use. There was a statistically significant difference between groups on the Addiction Severity Index (drug use severity and drug need domains) that favoured the topiramate arm; however, there was no statistically significant difference in cravings or depression symptoms between the study groups. Participants randomised to topiramate returned significantly fewer MA-positive UDS at Week 6, but this result was not sustained throughout the final 4 weeks of the treatment period \[[@CR55]\].

### Central Nervous System Stimulants {#Sec11}

Two studies reviewed examined dexamphetamine as stimulant agonist treatment. The first study reviewed 49 participants with MA dependence and prescribed 110 mg daily sustained-release oral dexamphetamine over 16 weeks. It measured MA use by self-report and analysis of hair, severity of dependence over time and treatment retention---finding no statistically significant difference between the study groups on planned analysis. Post-hoc analysis demonstrated a reduction in MA dependence symptoms in the dexamphetamine arm compared with placebo using the Leeds Dependence Questionnaire \[[@CR50]\]. Secondary analysis included withdrawal symptoms. The participants randomised to dexamphetamine demonstrated a greater reduction in withdrawal severity compared with placebo \[[@CR50]\]; however, participants were outpatients and continued MA use complicates the interpretation of withdrawal scores.

Another study examined sustained-release oral dexamphetamine (30 mg po BD) for 60 MA-dependent participants \[[@CR35]\]. The primary outcomes included safety and efficacy defined as abstinence from MA---measured by a new MA-positive UDS (measured twice weekly) and self-reported MA consumption. There was no significant difference between study groups on measures of MA consumption; however, the participants randomised to dexamphetamine reported significantly reduced MA withdrawal severity and cravings compared with placebo \[[@CR35]\], although these were secondary outcome measures and again in the context of continued MA use by outpatient participants.

Three studies examined sustained/extended-release oral methylphenidate in addition to the study reporting methylphenidate versus aripiprazole discussed earlier. All three were in the outpatient setting and used the same dose (54 mg po OD).

The first randomised 79 MA/AMPH-dependent participants for 22 weeks to methylphenidate or placebo, with abstinence (measured by twice-weekly UDS, and defined as the weekly percentage of AMPH/MA-positive results) as the primary outcome \[[@CR51]\]. Twenty-seven participants (34%) completed the study. In intention-to-treat analysis there were no differences in abstinence or study retention rates (defined by number of doses collected), although the methylphenidate arm achieved higher study retention from Week 6. The sample was heterogeneous, as participants were enrolled in both Finland, where all participants took intravenous AMPH, and New Zealand, where all participants smoked MA, but the results were analysed in aggregate. There was no concomitant psychosocial therapy.

Another study enrolled 110 MA-dependent participants in the USA with active study drug for 10 weeks followed by 4 weeks of blinded placebo treatment to encourage follow-up \[[@CR48]\]. Participants received weekly CBT and CM. There was no difference between study groups in self-reported MA use in planned analysis of the final 30 days of treatment; however, a secondary analysis of data from baseline to Week 10 found there were significantly fewer self-reported MA use episodes in the methylphenidate arm than placebo.

The final study enrolled 56 Iranian MA-dependent participants for 10 weeks of treatment examining craving as the primary outcome \[[@CR54]\]. At Week 10 of the study there was a reduction in craving in the treatment arm, and the treatment arm demonstrated fewer positive UDS and reduced depressive symptoms at Week 10 compared with the placebo arm.

### Other Central Nervous System Agents {#Sec12}

Modafinil was examined in four studies reviewed here, in doses of 200--400 mg daily. Three were conducted in outpatient settings \[[@CR25], [@CR38], [@CR59]\] and one in an inpatient withdrawal setting \[[@CR47]\]. One pilot withdrawal study examined feasibility and withdrawal symptoms in 19 participants prescribed 7 days of modafinil (200 mg po OD Days 1--5 and 100 mg po OD Days 6--7) versus placebo. There were no differences between study arms in retention or withdrawal symptoms \[[@CR47]\]. None of the other three studies demonstrated a difference in MA use, adherence or retention between study arms. One study analysed a subset of participants with the greatest adherence (\> 85%) to study treatment compared with other study participants randomised to modafinil and observed greater abstinence from MA in the \> 85% adherent participants; however, the comparison did not include the placebo group and external confounders were not identified or controlled for \[[@CR25]\].

### GABA Agonist/GABAergic Agents {#Sec13}

One 16-week outpatient study of 88 MA-dependent participants examined baclofen (20 mg OD three times daily \[TDS\]) and gabapentin (800 mg OD TDS) for their effects on MA use \[[@CR40]\]. Secondary outcomes included treatment retention, depression, cravings and adverse events. No differences were observed between study arms. Post-hoc analysis demonstrated higher probability of MA-negative urines was associated with medication adherence in all arms, higher in the treatment arm.

### Opioid Agonists {#Sec14}

Two Iranian studies reviewed examined opioid agonists, one buprenorphine \[[@CR57]\] and one buprenorphine and methadone \[[@CR24]\]. Both studies were in MA-dependent inpatient males with no co-occurring substance use disorder. In one 16-week study of 40 participants with concomitant psychosocial therapy (Matrix model), reduction in MA cravings and fewer MA-positive UDS were demonstrated among the buprenorphine (6 mg sublingual \[SL, i.e. applied under the tongue\] OD) arm as compared with the placebo arm during the treatment phase, trending back to baseline following cessation of medication \[[@CR57]\]. The second study examined buprenorphine (8 mg SL OD) versus methadone (40 mg po OD) over 17 days, with 20 participants in each study arm. There was a reduction in MA craving compared with placebo, and no participants produced MA-positive UDS in the study period, but the setting was a controlled inpatient environment \[[@CR24]\].

### Opioid Antagonists {#Sec15}

Five studies examined the opioid antagonist naltrexone, including two that used an extended-release formulation \[[@CR29], [@CR56]\] and one that used an implant \[[@CR63]\]. An additional study reported on naltrexone and n-acetyl cysteine (see below).

Results of the studies are conflicting. There was no difference in MA use by UDS in the treatment arm compared with placebo in the extended-release studies \[[@CR29], [@CR56]\]. One study of naltrexone (a single 4-week injection) reported on 37 of 52 randomised participants and found a reduction in past 30-day MA use, but relied entirely on self-report \[[@CR45]\], and there was a crossover in primary outcome measures given the past 30-day questionnaires were administered within 3 weeks of each other. One outpatient study of AMPH-dependent participants in Sweden reported fewer AMPH-positive UDS in the naltrexone (50 mg po OD) arm compared with placebo \[[@CR42]\], a result shared by the study examining naltrexone implants (1000 mg subcutaneously) administered to Russian participants with AMPH dependence \[[@CR63]\].

### 5HT3-Receptor Antagonist {#Sec16}

A single study has investigated ondansetron for the treatment of MA dependence \[[@CR44]\]. This four-arm trial assessed different doses of ondansetron (0.5 mg, 2 mg, 8 mg po OD) against placebo in measures of abstinence, use, severity of dependence, withdrawal, craving and retention in treatment. There was no observable difference in any outcome measure between doses or against placebo. The authors suggest that the nil result may be due to the short half-life of ondansetron (approximately 5 h) and suggest a sustained-release formulation or more aggressive dosing may give more efficacious results. At the time of this review no follow-up studies had been conducted.

### Partial Cholinergic Nicotinic Agonists {#Sec17}

A single, recent American study assessed varenicline (1 mg po BD) as a pharmacotherapy for MA dependence \[[@CR27]\]. There were no differences between treatment and placebo arms for any measures of dependence; however, there was a reduction in cigarettes smoked in the treatment arm (consistent with its licensed indication as a smoking cessation medication).

### Glutamatergic Agents {#Sec18}

Glutamatergic agents have been assessed, as either riluzole \[[@CR34]\], N-acetyl cysteine (NAC) \[[@CR53]\], or a combination of NAC and naltrexone \[[@CR37]\]. A recent trial of Iranian men found that riluzole (50 mg po OD) was associated with higher rates of retention in treatment and abstinence at Week 12, as well as overall improvements in a range of secondary outcomes \[[@CR34]\]. Efficacy for NAC is conflicted, however. When trialled as a combination of NAC (escalating dose to 2400 mg po OD) with naltrexone (escalating dose to 200 mg po OD), there was no difference between arms in measures of craving, use or psychological scales \[[@CR37]\]. Mousavi et al., however, found that NAC treatment (escalating dose to 1200 mg po OD) was associated with a reduction in craving. This paper did not report on secondary outcomes \[[@CR53]\]. Both studies had low participant numbers (*n* = 31 and *n* = 32, respectively). Mousavi et al. \[[@CR53]\] allowed weekly 'matrix model' psychological therapy to all participants, while Grant et al. \[[@CR37]\] did not provide any psychosocial support, and this may explain the discrepancies in results.

### CRF1 Antagonist {#Sec19}

We reviewed pexacerfont in one study, a 3-week trial of 51 Iranian men within residential treatment camps where treatment is not normally provided \[[@CR52]\]. Dosing was tapered from 300 mg po OD for the first week, to 200 mg po OD in Week 2 and 100 mg po OD in Week 3. While measures of craving reduced significantly more in the treatment arm than placebo, there was no difference in end-of-treatment abstinence between groups. Additionally, levels of temptation and depression, but not anxiety, withdrawal severity, or treatment effectiveness, improved favouring treatment.

### Benzodiazepine Antagonist/GABA Agonist/H1 Histamine Receptor {#Sec20}

The combination therapy of flumazenil (2 mg intravenous Days 1, 2, 3, 21, 22), gabapentin (titrated up to 1200 mg po OD) and hydroxyzine (50 mg po pre-intravenous medication and as required for sleep), marketed and trademarked as the 'PROMETA protocol', has been assessed twice in RCTs for MA dependence. Both trials were similar in terms of participant numbers and followed an identical medication protocol; however, results were conflicting. A 30-day trial found significantly improved craving scores, but no difference in use (missing UDS imputed as positive) \[[@CR65]\]. However, a 40-day trial conducted the same year found no differences in any measures, including craving \[[@CR49]\].

Discussion {#Sec21}
==========

Summary of Evidence {#Sec22}
-------------------

We reviewed 43 RCTs reporting on 4065 participants that examined 23 pharmacotherapies for SUD or drug dependence due to AMPH/MA with various outcomes pertaining to use and associated symptoms. While some drugs demonstrated results that were statistically significantly better than placebo outcomes, the studies were generally small and the samples biased and study protocol completion was low. This makes it impossible to recommend any pharmacotherapy as effective at this point in time, although there are some promising signals.

Reduction in Use {#Sec23}
----------------

There are a few pharmacotherapy candidates for the treatment of AMPH/MA dependence/use disorder that demonstrate some weak positive signals. The most consistent positive findings have been demonstrated with stimulant agonist treatment (dexamphetamine and methylphenidate), naltrexone and topiramate. Less consistent benefits have been shown with bupropion, the glutamatergic agent, riluzole, and antidepressant mirtazapine, whilst in general, antidepressant medications (e.g. SSRIs, TCAs) have not been effective in reducing AMPH/MA use.

Substitution/replacement medication approaches (i.e. agonist therapies) have demonstrated positive outcomes for other drug classes (e.g. nicotine replacement for tobacco/cigarettes, methadone for opioids, nabiximols for cannabis). Stimulant agonist treatment with dexamphetamine demonstrated promising results in post hoc and secondary analyses in the two studies reviewed here \[[@CR35], [@CR50]\], but predominantly with regard to withdrawal and craving symptoms in the context of continued AMPH/MA use. Methylphenidate delivered mixed results when assessed for varying outcomes. One study demonstrating higher retention rates in methylphenidate arms compared with placebo was limited by a heterogeneous study sample \[[@CR51]\]. Conversely, lower MA use by self-report in the methylphenidate arm compared with placebo was reported in a study (*n* = 110) that concurrently used CBT and CM \[[@CR48]\]; and reductions in craving and MA-positive UDS was reported in a study enrolling 56 participants \[[@CR54]\]. Other work in this area is ongoing. One study \[[@CR68]\] is currently examining 12 weeks of lisdexamfetamine (a pro-drug of dexamphetamine) versus placebo in a double-blind, RCT of MA-dependent (for at least 2 years) adults with baseline use of at least 14 of the prior 28 days.

The studies we reviewed here that examined the opioid antagonist naltrexone demonstrated conflicting results, but there were signals in both daily oral \[[@CR42]\] and long-acting formulations (i.e. subcutaneous implant) \[[@CR63]\] that naltrexone may reduce AMPH use. Recently, a large (*n* = 403) USA study of extended-release naltrexone (380 mg by intramuscular injection every 3 weeks) and bupropion (450 mg po OD) versus placebo completed enrolment. The primary outcome in this study was the percentage of UDS negative for MA during the 12 weeks of treatment, and results are pending (Trivedi et al.; ClinicalTrials.gov identifier: NCT03078075).

Topiramate was assessed in two studies reviewed here \[[@CR32], [@CR55]\], demonstrating reduced use and addiction severity compared with placebo. Furthermore, a secondary analysis of Elkashef et al. \[[@CR32]\] found higher responders within groups in a latent class analysis \[[@CR69]\], suggesting further studies with different eligibility criteria are warranted.

In baseline light-MA users or in men, bupropion demonstrated a reduction in MA use \[[@CR60]\]. Encouragingly, it also reduced concurrent tobacco use in participants \[[@CR66]\]. There are known interaction effects of nicotine and methamphetamine and a potential role of nicotine use in maintaining their co-use \[[@CR70]\].

One study of 86 men examining the benzothiazole riluzole demonstrated positive results \[[@CR34]\], with participants randomised to riluzole more likely to be retained in treatment and provide MA-negative UDS than those randomised to placebo. However, the study excluded participants who smoked cigarettes \> 3 days per week. Further studies in more diverse settings are required.

In men who have sex with men, the antidepressant mirtazapine reduced MA use and high-risk sexual behaviours, despite low medication adherence rates \[[@CR30]\]. In another study published by this group since our search, 120 cisgender males and transgender females who had sex with men and had MA use disorder were randomly assigned to mirtazapine 30 mg or placebo OD for 24 weeks with a further 12 weeks' follow-up \[[@CR71]\]. The primary outcome was MA-positive urines and secondary outcomes were sexual risk behaviours. Results were replicated, with reductions in both MA use and, although to a lesser extent than the first study and only at week 24, high-risk sexual behaviours (unprotected anal sex, number of partners) in participants randomised to mirtazapine as compared with placebo. Adherence was still imperfect, with an average of 28.1--39.5% medication adherence between the two arms. Participants received concomitant psychosocial therapy, and the authors suggest that mirtazapine may be a useful adjunct to psychosocial therapy, but only in the examined population.

There are currently other ongoing (recruiting) pharmacotherapy studies for AMPH/MA dependence. These include a double-blind placebo-controlled study of NAC (1200 mg po BD) in outpatients over 12 weeks \[[@CR72]\] currently recruiting in Australia. A phase I study examining the safety of ascending doses of pomaglumetad (an mGlutamate 2, 3 agonist) in 24 non-treatment-seeking participants is underway in the USA (Heinzerling et al.; ClinicalTrials.gov identifier: NCT03106571). A monoclonal antibody (IXT-m200) is being investigated in a randomised, placebo-controlled study as a single dose followed by four MA 'challenge doses' for its effects on the pharmacokinetics of MA and implications for its effects on drug liking (Ward et al.; ClinicalTrials.gov identifier: NCT03336866).

Treatment of Withdrawal Symptoms {#Sec24}
--------------------------------

It should be noted that our search strategy did not seek to identify studies that were specifically for the treatment of AMPH/MA withdrawal. However, five studies in our review focused on pharmacotherapy for MA withdrawal with withdrawal measures as the primary outcome. Three of these were included in a 2009 Cochrane Review \[[@CR73]\] of pharmacotherapies for AMPH withdrawal: a 1997 Thai study of amineptine in AMPH withdrawal \[[@CR43]\], a 2005 study examining mirtazapine in AMPH withdrawal \[[@CR46]\] and a 2008 study of mirtazapine in MA withdrawal \[[@CR31]\]. The Cochrane Review included a fourth study not reviewed here. The results of the meta-analyses undertaken in the Cochrane review demonstrated that amineptine did not reduce withdrawal symptoms or cravings compared with placebo, while the mirtazapine studies yielded mixed results, with one study demonstrating a small reduction in withdrawal symptoms on the AWQ for those randomised to mirtazapine, while the other demonstrated no difference in withdrawal symptoms on the Amphetamine Cessation Symptoms Assessment (ACSA) \[[@CR73]\]. The authors concluded that no medication was demonstrated to be effective in reducing AMPH withdrawal symptoms \[[@CR73]\].

Our review also identified several other studies published since the Cochrane Review reporting on withdrawal. In studies reviewed here examining withdrawal symptoms, no pharmacotherapy yielded robustly convincing results, while some had marked limitations; for example, in a recent Iranian study of riluzole (*n* = 74) \[[@CR34]\], secondary outcomes included the AWQ \[[@CR67]\]; however, it excluded any participants who smoked cigarettes more than 3 days per week, severely limiting its generalisability to stimulant consumers more broadly. Overall, the studies we reviewed signalled some potential promise in agonist therapy (dexamphetamine), CRF1 antagonist therapy (pexacerfont) and glutamatergic agents (riluzole) as potential pharmacotherapy candidates for MA withdrawal; however, further larger studies in the withdrawal context are required.

Although there are no evidence-based pharmacotherapies for AMPH/MA withdrawal \[[@CR74]\], standard of care generally includes symptomatic medications that target symptoms of withdrawal, including short-term use of benzodiazepines (e.g. diazepam) for anxiety, agitation and sleep disturbances, and antipsychotics (e.g. olanzapine) to manage any comorbid psychotic symptoms \[[@CR74]\]. Research is required on pharmacotherapy of stimulant withdrawal.

Treatment Setting {#Sec25}
-----------------

The majority of studies we reviewed were in the outpatient setting (*n* = 32, 74.4%), while a minority were conducted in inpatient settings (*n* = 5, 11.6%) and the rest were mixed or did not state the setting.

No study we reviewed directly compared outcomes between outpatient- and inpatient-treated participants. Importantly, we did not find any evidence that either treatment setting is superior to another for any of the outcomes we assessed. Hence, we suggest that criteria for the selection of treatment setting are based on clinical judgement and resources. For example, when managing stimulant withdrawal, the likelihood of severe complications (e.g. potential for severe psychiatric and cardiovascular complications during AMPH/MA withdrawal) may favour a period of inpatient treatment, whereas most AMPH/MA withdrawals could safely be completed in an ambulatory setting. Likewise, significant comorbidity (e.g. psychoses) may impact the ability to remain in ambulatory care during periods of treatment for AMPH/MA withdrawal or treatment. Other substance use and social environments will also feature when determining the best setting for clinical care \[[@CR75]\].

Similarly, the choice between residential or ambulatory treatment settings for longer term rehabilitation programmes may be determined by factors such as social supports, housing, employment and legal status of the patient.

Specific Populations {#Sec26}
--------------------

Nearly a quarter of the reviewed studies had no female participants, and male sex made up over 70% of the population across all studies. In nine of the studies reviewed here (20.9%), women were excluded by design. In some cases, this was due to the setting (e.g. male-only residential treatment centres), or studies conducted in specific populations (e.g. men who have sex with men), and in others the reason is not clearly stated. Research suggests women who take stimulants are more likely to become dependent consumers than men who take stimulants \[[@CR77]\]. While women are underrepresented in the reviewed studies as a proportion of the population overall, they may not be underrepresented as a proportion of the population who present for treatment. For example, in the US, the setting of over half of the studies reviewed here, only 36% of people estimated to have accessed treatment for illicit drug use in 2016 were female \[[@CR77], [@CR78]\].Women are more likely to encounter barriers to alcohol and other drug treatment than men, which may explain why they are under-represented in the studies reviewed here. This is due in large part to fear of losing access to children (e.g. due to mandatory reporting), and family responsibilities (lack of alternate options for childcare, etc.); women are also more likely to encounter economic barriers to treatment access than are men \[[@CR76]\].

Limitations {#Sec27}
-----------

Seventy-nine percent of the reviewed studies excluded participants with comorbid mental health diagnoses or concomitant medications prescribed for comorbid mental health diagnoses. Research suggests that transient psychotic symptoms are observed in up to 40% of MA-using populations \[[@CR79]\] and possibly more amongst treatment seekers. Forty-two percent of individuals who had used MA in the prior 12 months also reported being diagnosed or treated for a concurrent mental illness---three times as high as the non-illicit drug-using population \[[@CR80]\]. Among MA users, the majority report a lifetime prevalence of depression and anxiety \[[@CR81]\]. The exclusion of relatively common comorbidities such as polydrug dependence and mental health comorbidities limits the generalisability of many of the studies. For example, the role of antipsychotic and antidepressant medications may differ in patients presenting with psychosis or depression. Similarly, dependence to other substances such as alcohol, benzodiazepines or opioids is also likely to impact upon the safety and efficacy and choice of medications. Medications such as topiramate and naltrexone may be worth further examination in patients with comorbid alcohol use, whereas the role of naltrexone will vary according to opioid status; for example, responding to stimulant use in patients enrolled in opioid agonist treatment. Other comorbidities that continue to be poorly addressed include the management of patients with stimulant dependence and comorbid attention-deficit hyperactivity disorder (ADHD). Accurate diagnoses of ADHD in the context of AMPH/MA use can be complicated \[[@CR82]\], and there may be differential effects of medications in patients with both conditions. More research is required regarding pharmacological responses for patients with ADHD and stimulant use disorders. Another key area that has not been adequately addressed in clinical trials is the issue of comorbid sleep disturbances in patients using AMPH/MA, and the likely impact upon the role of different medications.

The studies reviewed here report on a variety of outcomes defined, measured and analysed differently across most publications. The broad selection of outcomes and measures render it difficult to meta-analyse or otherwise collectively synthesise the study results as reported. Future endeavours to standardise outcome measures across clinical trials in addiction medicine would make it easier to interpret study results collectively and better translate research results to clinical practice. Importantly, only three studies reviewed here (7%) provided information on adverse events/serious adverse events, despite the standard reporting format adopted by most publishers (CONSORT \[[@CR83]\]) including a minimum standard of harm reporting. This limits the capacity to appropriately assess the risk versus benefit of the pharmacotherapies reviewed here. We elected to include studies in this review irrespective of safety reporting, to provide a comprehensive review of the current status of research.

Although adherence was reported in most of the studies reviewed here, the methods and definitions were discordant across studies. Adherence thresholds varied and were often arbitrary. When plasma was assessed for active study drug/metabolite, there was no measurable metabolite included in the placebo, and the control data is therefore missing. Furthermore, presence of the study drug/metabolite does not necessarily indicate adherent consumption of the study drug, and authors varied in their assessments in that regard (i.e. present or not versus present at a defined level). Studies relying on pill count or self-report lacked critical appraisal of the results. For example, in one study where no participant returned un-used study drug, 100% adherence was inferred as opposed to examining if there were other reasons (e.g. discarding drug).

Definitions of efficacy of pharmacotherapies vary extensively. While some studies define success by abstinence from AMPH/MA, others consider a reduction in use to be a measure of treatment success. Abstinence as an outcome can be determined by self-report, or by negative UDS at time points pre-determined (see Table [5](#Tab5){ref-type="table"}). The desired goal of pharmacotherapy will likely vary depending on the patient, and must be patient-focused and clinically relevant.

Disparate criteria were also used when determining eligibility for a study; for example, the definition of 'low-use' (AMPH/MA) in the studies reviewed here was 5 days, 10 days and 18 days of the past 30 in various studies. This is an important limitation in synthesising data and results, and establishment of a clinically meaningful cut-off for regular and frequent use is imperative. Studies that analysed results by baseline frequency of MA/AMPH use often grouped days of use into categories defined as 'light use' or 'heavy use'. However, rationale for cut-points was often missing or ill-defined. In one study, consumption of MA was classified as 'heavy use' among participants providing three MA-positive UDS/fortnight, while in another study, 'heavy use' was classified as self-reported use of 18 days of the prior 30. In a 2007 paper, Hillhouse et al. \[[@CR19]\] found that frequency of MA use prior to treatment predicted both treatment performance and outcomes following treatment in a psychosocial intervention for MA dependence, reporting that participants with baseline use of \< 15 days in the 30 days prior to intake had better outcomes. Therefore, the disparity in groupings in pharmacotherapy research across studies and drugs makes it difficult to reliably recommend a strategy for determining cut-points. Further research and debate in this area is required to determine a clinically meaningful way of grouping frequency of use.

Studies conducted in (e.g. men who have sex with men) or excluding (e.g. women) specific populations are limited in their ability to generalise to other populations. The implications of contextual influences on outcomes are unknown. For example, no study we reviewed here assessed specific populations such as indigenous peoples. Similarly, while women were often excluded by the study design, no study examined only women. It is unknown how generalisable any of the results reviewed here are outside of the context in which they were conducted, and it is unwise therefore to combine results across populations.

Finally, because of the similarities in chemical structure and behavioural, psychological and physical effects of AMPH and MA \[[@CR84]\], we have included studies of AMPH and MA, and studies that did not distinguish between AMPH and MA. MA and AMPH may be knowingly or unknowingly consumed or co-consumed in uncertain concentrations, with variability over time and place. However, there is little data on which to assess whether there are distinct differences in use disorders due to these two substances; further assessment is required.

Future Directions {#Sec28}
-----------------

Future research should address small sample sizes and low participant retention and treatment adherence rates, leading to underpowered studies lacking meaningful results. Under-powered results can be avoided by planning recruitment for high attrition rates, collaborating on multi-centre research, potentially through clinical research networks, and a greater role for consumer and clinician engagement in the planning and establishment of trials. Medication adherence also needs to be better examined and monitored in trials, particularly when using medications with abuse liability (e.g. psychoactive medications such as stimulants).

Populations under-represented in the literature must also be addressed in future research. Harmonisation of outcomes and outcome measures to produce results that can be synthesised by meta-analyses should be a sector-wide imperative, to ensure better research synthesis. At a minimum, reduction in MA/AMPH use (e.g. days used or reduction in MA/AMPH-positive UDS) is required for assessment of efficacy. The reliance on extended periods of 'abstinence' as a primary endpoint does not always reflect participant treatment goals and is a somewhat insensitive marker of clinically meaningful change in substance use. However, further work is required to determine outcomes that are both clinically meaningful and meaningful to consumers.

Future research should address the need to understand the influence of co-existing conditions (e.g. ADHD, depression, comorbid substance use \[e.g. tobacco, alcohol, opioids, benzodiazepines\], psychosis, sleep disorders, complex trauma), increasing the likelihood of generating results that can be generalised to participants with comorbid conditions consistent with the underlying population.

Studies examining the efficacy of pharmacotherapy alone versus combined medication and psychosocial counselling are required to better understand the role each treatment modality may have. Provision of client-centred care requires future work to address the need to better understand concepts of treatment matching or stepped care. Not all patients may need or benefit from the same approach. Further, treatments may differ by dose and frequency (intensity) of use. Irrespective of the promise of pharmacotherapy, effective treatment of substance use disorders requires comprehensive biopsychosocial intervention.

Conclusions {#Sec29}
===========

While there are promising candidates, no pharmacotherapy for the treatment of AMPH/MA dependence/use disorder has provided convincing results. Studies are often limited by small sample sizes in defined populations, and with low treatment retention or completion rates. Different treatment options may be indicated for various degrees of severity of disorder. Combination therapies are yet to be explored. Optimal psychosocial interventions accompanying medication must also be considered. Further and substantial investment to determine effective pharmacotherapies is required.
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